How Obesity Creates Inflammation That Affects Your Brain and Mood

Key Points

• Obesity creates chronic, low-grade inflammation throughout your body that can reach your brain
• Inflammatory molecules interfere with serotonin and dopamine production, the same chemicals antidepressants target
• Inflammation accounts for 5-15% of the link between obesity and depression
• This inflammatory state helps explain why some people don’t respond well to traditional antidepressants
• Understanding your inflammatory status can guide more effective treatment choices

We’ve talked about the connections between obesity, depression, and anxiety. We’ve explored how stress hormones and behavioral changes link these conditions. Now I want to dive into what I consider one of the most important and underappreciated mechanisms connecting weight and mental health: inflammation.

This topic gets me genuinely excited because understanding inflammation has changed how I approach treatment for many of my patients. It explains patterns I was seeing clinically before I fully understood the biology. Why did some patients with obesity respond so poorly to antidepressants that usually work well? Why did certain patients see dramatic mood improvements when they addressed their metabolic health, even before significant weight loss occurred?

The answer, in many cases, is inflammation.

Most people think of inflammation as something that happens when you sprain your ankle or get an infection. The area gets red, swollen, warm, and painful. That’s acute inflammation, and it’s a normal, helpful response to injury or infection.

But there’s another type of inflammation that gets much less attention despite being incredibly common. Chronic, low-grade systemic inflammation. This type doesn’t cause obvious swelling or pain. You can’t see it or feel it directly. But it’s happening throughout your body, including in your brain, and it has profound effects on mood and mental health.

Obesity Is an Inflammatory State

Let me explain what’s actually happening at a biological level when someone carries excess adipose tissue (body fat).

For a long time, we thought of fat tissue as essentially passive storage. Just a place where your body stocked extra energy for later use. That view has completely changed. We now know that adipose tissue, particularly visceral fat (the fat around your organs), is metabolically active. It’s not just sitting there. It’s producing and secreting dozens of different molecules that affect the rest of your body.

When someone has obesity, particularly with significant visceral fat, their adipose tissue secretes increased amounts of inflammatory molecules called cytokines. The main ones we measure and worry about include interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-alpha), and C-reactive protein (CRP).

These inflammatory cytokines don’t stay localized in the fat tissue. They enter the bloodstream and circulate throughout your entire body, creating a state of chronic, low-grade systemic inflammation. This inflammatory state is consistently observed in people with obesity. The more excess fat someone carries, particularly visceral fat, the higher their inflammatory markers tend to be.

You can measure this. When I test inflammatory markers like CRP in patients with obesity, they’re often elevated even when the person has no infection or acute illness. Their body is in a constant state of mild inflammation.

This matters enormously for mental health because these inflammatory signals don’t just stay in your body below your neck. They can reach your brain.

How Inflammation Crosses Into Your Brain

Your brain is supposed to be protected. There’s something called the blood-brain barrier, which is essentially a selective filter that controls what can pass from your bloodstream into your brain tissue. This barrier protects your brain from toxins, pathogens, and other potentially harmful substances circulating in your blood.

But inflammatory cytokines can cross this barrier. The mechanisms are complex and not fully understood, but we know it happens. IL-6, TNF-alpha, and other inflammatory molecules can reach brain tissue and directly affect how your brain functions.

Once in the brain, these inflammatory signals cause a cascade of changes that affect neurotransmitter systems, the very same systems that regulate mood, motivation, and cognition.

Inflammation Disrupts Serotonin Production

Here’s where it gets really important for understanding depression treatment.

Serotonin is probably the most well-known neurotransmitter related to depression. Most antidepressants work by increasing serotonin availability in the brain. SSRIs (selective serotonin reuptake inhibitors) prevent serotonin from being reabsorbed too quickly, allowing it to stay active longer.

But here’s the problem. Serotonin is made from an amino acid called tryptophan. When inflammation is present in the brain, it activates an enzyme called IDO (indoleamine 2,3-dioxygenase). This enzyme diverts tryptophan away from serotonin production and toward a different pathway called the kynurenine pathway.

So instead of tryptophan being converted into serotonin, it gets shunted into producing compounds in the kynurenine pathway. Some of these compounds are actually neurotoxic. They can damage neurons and impair brain function. This is particularly problematic in areas of the brain involved in mood regulation, like the hippocampus and prefrontal cortex.

The result? Less serotonin available in your brain. And potentially toxic compounds being produced instead.

Think about the implications here. If you’re taking an SSRI that’s trying to make your existing serotonin work more efficiently, but inflammation is reducing how much serotonin your brain produces in the first place, the medication is fighting an uphill battle. You’re trying to make more efficient use of a depleted resource.

This helps explain why some people with obesity and depression don’t respond well to standard antidepressants. The inflammation is working against the medication.

I’ve had patients tell me they’ve tried multiple antidepressants with minimal benefit. When we test their inflammatory markers and find them elevated, it provides a potential explanation. The medications weren’t wrong choices necessarily. But we were missing a crucial factor that was undermining their effectiveness.

Dopamine Gets Affected Too

Serotonin gets most of the attention in depression discussions, but dopamine is equally important. Dopamine is crucial for motivation, pleasure, reward, and movement. When dopamine signaling is impaired, you get symptoms like fatigue, lack of motivation, inability to feel pleasure (anhedonia), and cognitive slowing.

Sound familiar? Those are core symptoms of depression.

Inflammation affects dopamine in multiple ways. It can reduce dopamine synthesis, impair dopamine receptor function, and increase dopamine breakdown. The inflammatory cytokines directly interfere with the enzymes and processes needed to make and use dopamine effectively.

This is particularly relevant for understanding the profound fatigue and lack of motivation that many people with both obesity and depression experience. It’s not just about serotonin. The inflammation is also hitting your dopamine system.

Some research suggests that inflammation might affect dopamine even more than serotonin in certain contexts. This could explain why some people with inflammation-driven depression don’t respond well to SSRIs (which primarily target serotonin) but might respond better to medications that affect dopamine, like bupropion.

The Numbers: How Much Does Inflammation Matter?

Research using sophisticated statistical methods has quantified how much inflammation contributes to the obesity-depression link. Studies using mediation analysis have found that systemic inflammation accounts for somewhere between 5% to 15% of the association between obesity and depression.

You might think 5-15% doesn’t sound like that much. But in terms of treatment, it’s highly significant.

First, that’s a portion of the depression that won’t respond to traditional antidepressants unless you address the inflammation. If 10% of someone’s depression is driven by inflammation, and you only use medications that target neurotransmitters without addressing inflammation, you’re leaving 10% of the depression untreated.

Second, for some individuals, the percentage is likely much higher than the average. Studies show population averages, but there’s substantial individual variation. Some people’s depression might be 30%, 40%, even 50% driven by inflammation. For those individuals, addressing inflammation isn’t a small piece of the puzzle. It’s potentially the most important intervention.

The research also shows that inflammation doesn’t affect all depression symptoms equally. It appears to have stronger effects on somatic symptoms (physical symptoms like fatigue, sleep disturbance, appetite changes, psychomotor slowing) compared to cognitive symptoms (negative thoughts, hopelessness, guilt).

This clinical pattern makes sense and matches what I see in practice. Patients with high inflammation often describe profound physical symptoms of depression. They’re exhausted. Everything feels like it takes enormous effort. Their body feels heavy. But they might not have as much of the negative thinking that we typically associate with depression. Or the physical symptoms might be disproportionately severe compared to their cognitive symptoms.

The HPA Axis Gets Involved Too

We’ve talked about the HPA axis (hypothalamic-pituitary-adrenal axis) in previous articles as the body’s stress response system. Inflammation affects this system as well, creating another pathway through which obesity influences mental health.

Inflammatory cytokines can directly activate the HPA axis, leading to elevated cortisol production. This creates a situation where inflammation is both a consequence of obesity and a cause of HPA axis dysregulation. The dysregulated HPA axis then contributes to both worsening obesity (through cortisol’s effects on fat storage and appetite) and worsening mood.

Inflammation also impairs the normal feedback loops that are supposed to regulate the HPA axis. Your HPA axis should activate in response to stress and then turn off when the stressor is gone. Inflammation interferes with the “turn off” signal. So the HPA axis stays activated longer than it should, producing excess cortisol even when there’s no current stressor.

This is another vicious cycle. Obesity causes inflammation. Inflammation dysregulates the HPA axis. HPA axis dysregulation worsens both obesity and mood. The worsening obesity creates more inflammation. And so on.

Specific Subtypes of Depression

The inflammation connection appears particularly strong for certain subtypes of depression. Research has found that atypical depression, which is characterized by increased appetite, weight gain, and extreme fatigue, shows particularly high levels of inflammatory markers.

This makes biological sense. If inflammation is driving depression partly through metabolic effects and effects on appetite regulation, you’d expect to see increased appetite and weight gain as features of that depression. That’s exactly what atypical depression looks like clinically.

Studies have also found elevated levels of leptin (a hormone produced by fat tissue) in people with atypical depression. Leptin itself can be pro-inflammatory. So there’s a pattern where certain metabolic and inflammatory markers cluster together with specific depression symptoms.

This has treatment implications. If someone presents with atypical depression features (increased appetite, weight gain, fatigue, feeling physically heavy), I’m particularly alert to the possibility that inflammation is playing a major role. That influences which treatments I consider.

Neural Plasticity and Brain Structure

Inflammation doesn’t just affect neurotransmitters in the moment. Chronic inflammation can cause longer-term changes in brain structure and function.

Research shows that inflammation impairs neural plasticity, which is the brain’s ability to form new connections and adapt to changing circumstances. Neural plasticity is thought to be crucial for recovering from depression. Some theories suggest that antidepressants work partly by restoring neural plasticity.

If inflammation is impairing plasticity, that’s another mechanism through which it could make depression harder to treat. You’re not just fighting the immediate neurotransmitter effects. You’re also dealing with impaired brain adaptability.

Studies using brain imaging have found associations between inflammatory markers and changes in brain structure, particularly in areas like the hippocampus (involved in memory and mood regulation) and prefrontal cortex (involved in executive function and mood regulation). Higher inflammation is associated with reduced volume or altered function in these regions.

Are these changes reversible? We don’t know for certain, but there’s reason for hope. Some studies suggest that reducing inflammation can improve brain function and potentially even restore some structural changes. The brain has remarkable capacity for healing when given the right conditions.

Why This Matters for Treatment

Understanding the role of inflammation fundamentally changes how I approach treatment for patients with both obesity and depression.

Testing becomes important. I often check inflammatory markers in patients with treatment-resistant depression, particularly if they also have obesity or metabolic syndrome. A high-sensitivity CRP test is relatively inexpensive and widely available. Other markers like IL-6 can be measured but are more specialized.

When I find elevated inflammation, it provides valuable information. It suggests that addressing inflammation should be part of the treatment strategy, not an afterthought.

Medication choices shift. Some antidepressants have better evidence for working in the presence of inflammation. Bupropion, which affects dopamine and norepinephrine rather than primarily serotonin, might be a better choice for someone with high inflammation. Some research suggests that SNRIs (serotonin-norepinephrine reuptake inhibitors) might work better than SSRIs in the presence of inflammation, though the evidence is still evolving.

There’s also growing interest in medications and supplements with anti-inflammatory properties as adjuncts to standard antidepressants. Things like omega-3 fatty acids, which have anti-inflammatory effects, show some promise for improving antidepressant response in people with elevated inflammation.

Lifestyle interventions gain importance. Exercise has powerful anti-inflammatory effects. Even modest amounts of regular physical activity can reduce inflammatory markers. Dietary changes that reduce inflammation (which we’ll discuss in more detail in a future article) become not just about weight loss but about directly addressing a mechanism driving depression.

Sleep optimization matters because poor sleep worsens inflammation. Stress reduction is important because chronic stress elevates inflammation. All of these pieces fit together.

Weight loss itself becomes a psychiatric intervention. When someone with obesity and elevated inflammation successfully loses weight through healthy means, their inflammatory markers typically decrease. That reduction in inflammation can improve mood independent of any psychological benefits from weight loss. The biological improvement in brain chemistry contributes to improved mental health.

I’ve seen patients achieve significant improvement in depression that had been resistant to multiple medication trials once they successfully addressed their metabolic health and reduced inflammation. It’s not that the previous medications were wrong. It’s that we were missing a crucial piece of the picture.

What You Can Do With This Information

If you have both obesity and depression, particularly if you haven’t responded well to antidepressants or if you have prominent fatigue and physical symptoms, it’s worth considering whether inflammation might be playing a role.

You can ask your doctor to check your inflammatory markers. A high-sensitivity CRP test is a good starting place. Normal values are generally considered to be below 3 mg/L, but even values in the 1-3 mg/L range suggest low-grade inflammation that could be relevant.

If your CRP or other inflammatory markers are elevated, that information is useful. It suggests that interventions targeting inflammation should be part of your treatment plan. That might include anti-inflammatory dietary changes, regular exercise, optimization of sleep, stress reduction, and possibly anti-inflammatory supplements or medications.

It also provides a framework for understanding why previous treatments might not have worked as well as hoped. The problem wasn’t that you were treatment-resistant or that the medications were wrong. The problem was that an important underlying factor wasn’t being addressed.

The Bigger Picture

Inflammation is one piece of a larger puzzle connecting obesity and mental health. It doesn’t exist in isolation. It interacts with stress hormones, sleep, diet, exercise, gut health, and other factors we’ll explore in upcoming articles.

But it’s an important piece. For some people, it might be the most important piece. Understanding the role inflammation plays in your particular situation helps guide more effective, targeted treatment.

The good news is that inflammation is modifiable. Unlike some aspects of biology that are fixed, you can actually reduce inflammation through various interventions. That means this isn’t just interesting biology. It’s actionable information that can lead to real improvements in both metabolic and mental health.

In my practice, understanding and addressing inflammation has been one of the most valuable additions to how I approach treatment for patients dealing with both weight and mood concerns. It’s shifted many patients from feeling stuck and treatment-resistant to finally making meaningful progress.

In the next article, we’ll explore the flip side of this relationship. We’ll look at how psychological stress contributes to obesity through behavioral, hormonal, and metabolic pathways. Understanding both directions of this relationship gives us a complete picture of how to break the cycle.

References

1. Shelton RC, Miller AH. Eating Ourselves to Death (And Despair): The Contribution of Adiposity and Inflammation to Depression. Progress in Neurobiology. 2010;91(4):275-99.
   
2. Capuron L, Lasselin J, Castanon N. Role of Adiposity-Driven Inflammation in Depressive Morbidity. Neuropsychopharmacology. 2017;42(1):115-128.
   
3. Wang X, Liang X, Jiang M, et al. Systemic Inflammation as a Mediator in the Link Between Obesity and Depression: Evidence From a Nationwide Cohort Study. BMC Psychiatry. 2025;25(1):449.
   
4. Huet L, Delgado I, Dexpert S, et al. Relationship Between Body Mass Index and Neuropsychiatric Symptoms: Evidence and Inflammatory Correlates. Brain, Behavior, and Immunity. 2021;94:104-110.
   
5. Oracz AJ, Zwierz M, Naumowicz M, Suprunowicz M, Waszkiewicz N. Relationship Between Obesity and Depression Considering the Inflammatory Theory. International Journal of Molecular Sciences. 2025;26(11):4966.
   
6. Chu K, Cadar D, Iob E, Frank P. Excess Body Weight and Specific Types of Depressive Symptoms: Is There a Mediating Role of Systemic Low-Grade Inflammation? Brain, Behavior, and Immunity. 2023;108:233-244.
   
7. Zeng Y, Chourpiliadis C, Hammar N, et al. Inflammatory Biomarkers and Risk of Psychiatric Disorders. JAMA Psychiatry. 2024;81(11):1118-1129.
   
8. Martins LB, Monteze NM, Calarge C, Ferreira AVM, Teixeira AL. Pathways Linking Obesity to Neuropsychiatric Disorders. Nutrition. 2019;66:16-21.
   
9. André C, Dinel AL, Ferreira G, Layé S, Castanon N. Diet-Induced Obesity Progressively Alters Cognition, Anxiety-Like Behavior and Lipopolysaccharide-Induced Depressive-Like Behavior: Focus on Brain Indoleamine 2,3-Dioxygenase Activation. Brain, Behavior, and Immunity. 2014;41:10-21.
   
10. Milaneschi Y, Lamers F, Peyrot WJ, et al. Genetic Association of Major Depression With Atypical Features and Obesity-Related Immunometabolic Dysregulations. JAMA Psychiatry. 2017;74(12):1214-1225.
    
11. Amerikanou C, Valsamidou E, Kleftaki SA, et al. Peripheral Inflammation Is Linked With Emotion and Mental Health in People With Obesity. A “Head to Toe” Observational Study. Frontiers in Endocrinology. 2023;14:1197648.
    
12. Steptoe A, Frank P. Obesity and Psychological Distress. Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences. 2023;378(1888):20220225.